Pamela Layton, Board of Directors

Pamela Layton, is a board member and one of the founders of 4immune Therapeutics. She started her career in finance at Bankers Trust Company and Chemical Bank in New York and went on to found multiple companies based on leading-edge technologies. She founded and led the TriGuard Group with its interactive software architecture from conception to market with a patented server-based security notification platform that was partnered with a subsidiary company of ADT for national distribution.

She then went on to form Parcell Laboratories around a novel adult stem cell discovered at Harvard and the Brigham. The cell was brought through the development process and into the clinic for use as a pure-cellular allograft for spinal fusion surgeries. Mrs. Layton was the president of Bioarray Genetics that developed a predictive diagnostic test for breast cancer treatments, followed by her position as CEO of Xenotherapeutics Foundation dedicated to the use of genetically modified swine skin as acute coverage for burn injuries, a technology that was recently recognized by an award from the American Burn Association.

She was awarded the distinction of Certified Tissue Bank Specialist by the American Association of Tissue Banks in 2013 and holds multiple U.S. and European patents on the ELA stem cell (one of only three stem cells to be patented worldwide) and its therapeutic applications, as well as the patent for the Interactive Information Management Network that allows security system notifications to be routed per database configurations for information flow optimization.

Pamela sits on the board of The Pioneer Institute, the Advisory Board of Mass Innovation Network and multiple emerging companies.